Press release
Advanced Gastric Carcinoma Pipeline: 50+ Visionary Companies Pioneering the Next Generation of Therapies and Drug Development
Advanced Gastric Carcinoma Pipeline
DelveInsight's "Advanced Gastric Carcinoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the advanced gastric carcinoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging advanced gastric carcinoma drugs, the advanced gastric carcinoma pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Curious about the latest breakthroughs in advanced gastric carcinoma treatment? Discover cutting-edge drugs and the evolving pipeline-click here to explore: https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report
• DelveInsight's advanced gastric carcinoma pipeline analysis depicts a strong space with 50+ active players working to develop 50+ pipeline drugs for advanced gastric carcinoma treatment.
• The leading advanced gastric carcinoma companies include Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others are evaluating their lead assets to improve the advanced gastric carcinoma treatment landscape.
• Key advanced gastric carcinoma pipeline therapies in various stages of development include Camrelizumab, Pamiparib, Mitoxantrone Hydrochloride Liposome, Catumaxomab, Ipilimumab, Relatlimab, FLX475, DP303c, IDX-1197, HLX22, Olaparib, LCAR-C18S, ALX148, KN026, Atezolizumab, Sintilimab, QL1604, NC410, KH903, GQ1001, Amivantamab, IMU-131, BT8009, VE800, CPL304110, ARX788, MRG002, SEA-TGT, and others.
• In March 2025, the FDA granted traditional approval for frontline KEYTRUDA in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma with PD-L1 CPS ≥1. Additionally, the FDA granted orphan drug designation to the anti-HER2 monoclonal antibody HLX22 for the treatment of patients with gastric cancer.
• In January 2025, the FDA approved tislelizumab-jsgr (tislelizumab) for the first-line treatment of unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adult patients with PD-L1-expressing tumors.
• In December 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), announced the FDA approval of TEVIMBRA® (tislelizumab-jsgr) in combination with platinum and fluoropyrimidine-based chemotherapy for first-line treatment of unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults with PD-L1 expression (≥1).
• In October 2024, Astellas Pharma Inc. announced the FDA approval of VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma with CLDN18.2 positivity, determined by an FDA-approved test. VYLOY is the first CLDN18.2-targeted therapy approved in the U.S.
Request a sample and discover the recent breakthroughs happening in the advanced gastric carcinoma pipeline landscape @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Gastric Carcinoma Overview
Advanced stomach cancer occurs when cancer originating in the stomach spreads to other parts of the body, such as the liver, lungs, lymph nodes, or the peritoneum. The symptoms vary depending on the affected organs, but common signs include unexplained weight loss, nausea, stomach pain, difficulty swallowing, and fatigue.
At an advanced stage, treatment focuses on symptom management and disease control. External radiotherapy can help alleviate discomfort, while chemotherapy, targeted therapy, and radiotherapy may reduce symptoms. Additional interventions, such as laser therapy or stents, can address blockages in the stomach. In some cases, surgery is used to relieve obstructions. Laser therapy, which uses high-intensity beams to destroy cancer cells, is another option for symptom management in advanced stomach cancer.
Find out more about advanced gastric carcinoma @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Gastric Carcinoma Treatment Analysis: Drug Profile
Camrelizumab: JiangsuHengrui Medicine
Camrelizumab (HR 301210, INCSHR 1210, SHR 1210) is a humanized IgG4-kappa monoclonal antibody designed to target the programmed cell death-1 (PD-1) receptor. It is currently undergoing Phase III clinical trials for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Pamiparib: BeiGene
Pamiparib (BGB-290) is an experimental small molecule inhibitor of PARP1 and PARP2. It is being studied as a monotherapy in pivotal clinical trials in China for recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. Globally, it is under development both as a monotherapy and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), to treat various solid tumors.
Learn more about the novel and emerging advanced gastric carcinoma pipeline therapies @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Gastric Carcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Advanced Gastric Carcinoma Pipeline Report
• Coverage: Global
• Key Advanced Gastric Carcinoma Companies: Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
• Key Advanced Gastric Carcinoma Pipeline Therapies: Camrelizumab, Pamiparib, Mitoxantrone Hydrochloride Liposome, Catumaxomab, Ipilimumab, Relatlimab, FLX475, DP303c, IDX-1197, HLX22, Olaparib, LCAR-C18S, ALX148, KN026, Atezolizumab, Sintilimab, QL1604, NC410, KH903, GQ1001, Amivantamab, IMU-131, BT8009, VE800, CPL304110, ARX788, MRG002, SEA-TGT, and others.
Dive deep into rich insights for drugs used for advanced gastric carcinoma treatment; visit @ https://www.delveinsight.com/report-store/advanced-gastric-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Advanced Gastric Carcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Advanced Gastric Carcinoma Pipeline Therapeutics
6. Advanced Gastric Carcinoma Pipeline: Late-Stage Products (Phase III)
7. Advanced Gastric Carcinoma Pipeline: Mid-Stage Products (Phase II)
8. Advanced Gastric Carcinoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Gastric Carcinoma Pipeline: 50+ Visionary Companies Pioneering the Next Generation of Therapies and Drug Development here
News-ID: 3988807 • Views: …
More Releases from DelveInsight
Sensorineural Hearing Loss Clinical Trials Analysis 2025: Emerging Regenerative …
DelveInsight's "Sensorineural Hearing Loss Clinical Trials Analysis, 2025" describes a rapidly evolving pipeline targeting both restoration of inner-ear structures and symptomatic improvement. Ongoing programs span hair cell regeneration via small molecules and biologics, AAV- and non-viral gene-replacement or gene-editing strategies for monogenic deafness, cell-based therapies (supporting synaptic reconnection), and cochlear neuromodulation advancements to augment residual hearing. Trials increasingly pair novel delivery methods (e.g., intracochlear, round-window) with precision patient selection based…
Cell and Gene Therapy in Parkinson's Disease Clinical Trials Analysis 2025: Dise …
DelveInsight's "Cell and Gene Therapy in Parkinson's Disease - Clinical Trials Analysis, 2025" highlights a diversified development landscape pursuing symptomatic relief and disease modification. Programs include dopamine-restorative cell implants, neuroprotective gene therapies targeting α-synuclein aggregation or neuroinflammation, and circuit-targeted gene delivery to rebalance basal ganglia networks. Trials incorporate advanced delivery (stereotactic infusion), standardized imaging and molecular biomarkers, and combination strategies pairing cell/gene therapy with neuromodulation.
Pivotal and late-phase trials focus on…
Staphylococcal Infections Clinical Trials Analysis 2025: New Antibacterials, Ant …
DelveInsight's "Staphylococcal Infections Clinical Trials Analysis, 2025" outlines a focused effort to tackle antibiotic resistance and severe invasive disease. Active programs include novel small-molecule antibacterials with activity against MRSA, anti-virulence and quorum-sensing inhibitors, monoclonal antibodies targeting toxins and surface proteins, and host-directed immunotherapies to enhance clearance. Trials cover a range of indications from complicated skin and soft tissue infections to bacteremia and prosthetic-joint infections, with increasing attention on combination regimens…
Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Analysis, 2025: Targeted …
DelveInsight's "Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Analysis, 2025" captures an expanding set of symptomatic and mechanism-based approaches to address an under-treated, QoL-limiting symptom. Development includes neuromodulators that dampen hypersensitive cough reflexes, monoclonal antibodies against inflammatory mediators implicated in fibrotic cough, and novel inhaled agents to modify airway sensory signaling. Trials increasingly integrate digital cough monitoring, patient-reported cough-specific scales, and physiological cough reflex testing for objective and subjective assessment.
Registrational…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
